Inhibition of efflux pumps by FDA-approved drugs oxiconazole and sertaconazole restores antibiotic susceptibility in multidrug-resistant <i>S. aureus</i>.

ABSTRACT: Antibiotic resistance in Staphylococcus aureus causes major concern worldwide. In S. aureus, efflux pumps are mostly responsible for the development of multidrug resistance. Active removal of antibiotics from cells by S. aureus efflux pumps, including NorA, NorB, AbcA, and MepA, helps to lower their intracellular concentration and effectiveness. The present study examined two FDA-approved antifungal medications, oxiconazole and sertaconazole, as possible efflux pump inhibitors (EPIs) against multidrug-resistant S. aureus. Our results showed that both drugs reduced the efflux pump activity of drug-susceptible (ATCC25923) and multidrug-resistant (Mu50) S. aureus strains. While sertaconazole inhibited the efflux pumps without changing the efflux rate, oxicon

SUBMITTER: Ojha S 

PROVIDER: S-EPMC12406663 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature